Amit Sachdev - 17 May 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 May 2021
Net transactions value
-$9,736
Form type
4
Filing time
19 May 2021, 16:08:20 UTC
Next filing
16 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $1,725 -8 -0.02% $215.59 40,170 17 May 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale $6,925 -32 -0.08% $216.40 40,138 17 May 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale $1,086 -5 -0.01% $217.27 40,133 17 May 2021 Direct F1, F3, F5
holding VRTX Common Stock 882 17 May 2021 401(k)
holding VRTX Common Stock 7,368 17 May 2021 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $215.59 (range $214.94 to $215.93).
F3 Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $216.40 (range $215.95 to $216.91).
F5 Open market sales reported on this line occurred at a weighted average price of $217.27 (range $217.05 to $217.46).